Edition:
India

Valbiotis SA (ALVAL.PA)

ALVAL.PA on Paris Stock Exchange

2.18EUR
13 Dec 2019
Change (% chg)

€-0.02 (-0.91%)
Prev Close
€2.20
Open
€2.30
Day's High
€2.30
Day's Low
€2.16
Volume
24,861
Avg. Vol
9,620
52-wk High
€4.25
52-wk Low
€1.98

Latest Key Developments (Source: Significant Developments)

Valbiotis Launches Capital Increase Of 7.2 Million Euros
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - VALBIOTIS SA ::VALBIOTIS LAUNCHES A CAPITAL INCREASE WITH MAINTENANCE OF THE RIGHT PREFERENTIAL SUBSCRIPTION (SDA).SUBSCRIPTION PRICE : EUR 2.35 PER SHARE.SUBSCRIPTION PERIOD: FROM OCTOBER 16, 2019 TO OCTOBER 28, 2019 INCLUSIVE.CAPITAL INCREASE OF EUR 7.2 MILLION WHICH MAY BE INCREASED TO EUR 8.3 MILLION IN EVENT OF EXERCISE OF THE EXTENSION CLAUSE.NEW STRATEGIC PRIORITY: CONCLUDE BEFORE END-2020 PARTNERSHIP WITH MAJOR HEALTHCARE PLAYER THAT WILL PROVIDE FUNDING NEEDED TO FINALIZE CLINICAL DEVELOPMENT OF VALEDIA.AROUND 2/3 TO BE DEDICATED TO RESEARCH AND DEVELOPMENT, 1/3 TO "MARKET ACCESS".  Full Article

Valbiotis Publishes Additional Results From Phase IIa Study Of Valedia
Monday, 2 Sep 2019 

Sept 2 (Reuters) - Valbiotis SA ::ADDITIONAL POSITIVE RESULTS FROM THE PHASE IIA CLINICAL STUDY OF VALEDIA.RESULTS OF PHASE IIA STUDY HAVE EXCEEDED ALL SET OBJECTIVES AND THE OVERALL EFFICACY OF VALEDIA IN SUBJECTS AT RISK OF METABOLIC DISEASES HAS BEEN PROVEN.VALEDIA SIGNIFICANTLY REDUCED BLOOD GLUCOSE LEVELS, AND BODY WEIGHT COMPARED TO PLACEBO.  Full Article

Valbiotis: Positive Results From Phase IIa Clinical Study Of Valedia
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Valbiotis SAS ::VALBIOTIS ANNOUNCES POSITIVE RESULTS FROM THE PHASE IIA CLINICAL STUDY OF VALEDIA®, NOW THE FIRST PRODUCT PROVEN EFFECTIVE IN PEOPLE WITH PREDIABETES.VALEDIA SIGNIFICANTLY REDUCED FASTING AND POST-PRANDIAL BLOOD GLUCOSE LEVELS, TWO RISK FACTORS FOR TYPE 2 DIABETES, COMPARED TO PLACEBO..VALEDIA SIGNIFICANTLY REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE, COMPARED TO PLACEBO..VALEDIA IS NOW FIRST CLINICALLY VALIDATED PRODUCT DESIGNED FOR PEOPLE WITH PREDIABETES THAT REDUCES RISK FACTORS FOR TYPE 2 DIABETES.COMMERCIALIZATION IS PLANNED FOR 2021, AS PREVIOUSLY ANNOUNCED..  Full Article

Valbiotis Succeeds In Industrial Production Of Valedia
Tuesday, 28 May 2019 

May 28 (Reuters) - VALBIOTIS SAS ::VALBIOTIS SUCCEEDS IN THE INDUSTRIAL PRODUCTION OF VALEDIA®, A MAJOR SCIENTIFIC INNOVATION FOR PREDIABETIC PEOPLE, IN COLLABORATION WITH THE PIERRE FABRE GROUP.CONFIRMATION OF VALBIOTIS'S CAPACITY TO PRODUCE VALEDIA® IN COMPLIANCE WITH NORTH AMERICAN AND EUROPEAN INDUSTRIAL STANDARDS.A KEY STAGE IN HEALTH CLAIM APPLICATION FOR TWO LEADING MARKETS WORLDWIDE, NORTH AMERICA AND EUROPE.ACCOMPLISHMENT DUE TO COMBINED EXPERTISE OF VALBIOTIS AND PIERRE FABRE GROUP, WHICH SPECIALIZES IN INDUSTRIAL MANUFACTURE OF PLANT-BASED PRODUCTS.RESULTS OF FIRST INTERNATIONAL PHASE IIA STUDY ARE EXPECTED BEFORE 31 JULY 2019.LAUNCH OF VALEDIA(®) IS PLANNED FOR 2021, WITH A HEALTH CLAIM FOR REDUCING RISK OF TYPE 2 DIABETES.TOTUM-63 HAS ALREADY BEEN PROVEN SAFE AND EFFECTIVE IN HEALTHY HUMAN VOLUNTEERS DURING A PHASE I/II CLINICAL STUDY.THIS STEP COMPLETES OUR HEALTH CLAIM APPLICATION AND SUPPORTS OUR NEGOTIATIONS WITH A PARTNER COMPANY TO MARKET PRODUCT IN 2021 - CEO.  Full Article

Valbiotis FY Recurring Operating Loss Widens to 4.8 Million Euros
Friday, 8 Mar 2019 

March 8 (Reuters) - VALBIOTIS SAS ::CASH POSITION AT DEC 31, 2018 AT EUR 7.4 MILLION.FY NET LOSS EUR 5.0 MILLION VERSUS LOSS OF EUR 2.4 MILLION YEAR AGO.VALEDIA: RESULTS OF PHASE IIA EXPECTED IN SUMMER 2019.FY RECURRING OPERATING LOSS EUR 4.8 MILLION VERSUS LOSS EUR 2.3 MILLION.VALEDIA: CONFIRMATION OF COMMERCIALIZATION BY 2021.  Full Article

Valbiotis: Expansion Of Application For Valedia To Include NASH Prevention
Monday, 12 Nov 2018 

Nov 12 (Reuters) - VALBIOTIS SAS ::VALBIOTIS ANNOUNCES EXPANSION OF APPLICATION FOR VALEDIA TO INCLUDE NASH PREVENTION.NEW RESULTS DEMONSTRATE CLINICAL POTENTIAL OF VALEDIA FOR NASH RISK REDUCTION..STUDIES ON VALEDIA SHOW COMPLETE REVERSION OF HEPATIC STEATOSIS IN AN IN VIVO PRECLINICAL MODEL.PHASE II CLINICAL DEVELOPMENT OF VALEDIA FOR NASH RISK REDUCTION WILL START WITH A PHASE IIA RANDOMIZED WITH PLANNED LAUNCH IN 2019 IN A TARGET POPULATION WITH NAFL.BASED ON THESE RESULTS, CO PLANS TO LAUNCH PHASE II CLINICAL STUDIES IN ADDITION TO ONGOING STUDIES FOR THE RISK REDUCTION OF TYPE 2 DIABETES.  Full Article

Valbiotis Signs Scientific Partnership With CarMeN
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - VALBIOTIS SAS ::SIGNS SCIENTIFIC PARTNERSHIP WITH CARMEN.NEW SCIENTIFIC DATA EXPECTED IN THE COMING MONTHS.  Full Article

Valbiotis Launches Capital Increase By Private Placement For Maximum Of 20 Percent Of Capital
Monday, 1 Oct 2018 

Oct 1 (Reuters) - VALBIOTIS SAS ::LAUNCHES CAPITAL INCREASE BY PRIVATE PLACEMENT FOR MAXIMUM OF 20 PERCENT OF CAPITAL.  Full Article

Valbiotis Reports H1 Operating Loss Of 1.9 Million Euros
Friday, 21 Sep 2018 

Sept 21 (Reuters) - VALBIOTIS SAS ::AT END JUNE CASH POSITION AMOUNTED TO CIRCA EUR 8 MILLION.H1 NET LOSS EUR 1.9 MILLION VERSUS LOSS EUR 0.4 MILLION YEAR AGO.H1 OPERATING LOSS EUR 1.9 MILLION VERSUS LOSS EUR 0.3MLN YEAR AGO.H1 OPERATIONAL REVENUE EUR 0.5 MILLION VERSUS EUR 0.4 MILLION YEAR AGO.  Full Article

Valbiotis Obtains Patent For Valedia® In United States​
Thursday, 15 Mar 2018 

March 15 (Reuters) - VALBIOTIS SAS ::‍VALBIOTIS OBTAINS STRATEGIC PATENT FOR VALEDIA® IN UNITED STATES​.  Full Article